The present study has investigated the therapeutic efficiency of GLPG1790 against HCT116 and HCT15 CRC cell lines, both expressing a mutated form of KRAS in addition to either a wild-type p53 protein (p53WT) or mutated p53 (p53MT), respectively [14]. The gene discussed is KRAS; the disease is colorectal carcinoma.